Runtime
02:00
Researchers have found that combining ipilimumab (YervoyTM) and vemurafenib (Zelboraf®) can cause side effects for patients with metastatic melanoma. This research is reported in a letter in the April 4 issue of the New England Journal of Medicine by Memorial Sloan-Kettering medical oncologist Jedd Wolchok, medical oncologist and research fellow Margaret Callahan, and colleagues from Memorial Sloan-Kettering, Dana Farber Cancer Institute, and the University of California, Los Angeles.
Speaker(s)
Related Cancer & Treatment Information
See Videos Related to:
